Hoth Therapeutics, Inc. has announced a new clinical study under a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs and the Foundation for Atlanta Veterans Education and Research (FAVER). The study aims to evaluate glial cell-derived neurotrophic factor (GDNF) as a novel therapy for obesity and hepatic steatosis, by conducting a head-to-head comparison against semaglutide. The research will take place at the Atlanta VA Medical Center, utilizing both standard diet-induced obese mice and human liver chimeric mouse models. This marks the first pharmacologic test of GDNF in human liver-engrafted mice, which could pave the way for new metabolic applications. Hoth Therapeutics will supply GDNF for the study, while the VA will retain data rights and share de-identified results in compliance with HIPAA. Results of the study have not yet been presented.